,NAFLD—which patients should have hepatocellular carcinoma surveillance?

• 作 者: Zeynep C. Elcioglu Helen L. Reeves
• 机 构: Newcastle upon Tyne Hospitals NHS Foundation Trust,Newcastle upon Tyne,UK“,”Northern Institute for C
• 出 处: 肝胆外科与营养
• 发表日期: 2017年5期

Studies linking non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) and cryptogenic cirrhosis to the development of hepatocellular carcinoma (HCC) began to emerge 15 years ago (1,2). A number of large registry or cohort studies have subsequently confirmed these observations in the United States (3,4), Europe (5) and the Asia Pacific (6,7).